The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...
How far would you go to have lighter skin? Influencer admits to bleaching his skin with disinfectant
Influencer and software developer, Masheane Sefuthi, has left fans stunned after he admitted having bleached his skin using an unconventional method. The Youtuber, who goes by Mashie online ...
Really a disastrous decision." Congress directed NHTSA in the 2021 infrastructure law to establish minimum-performance standards for automatic emergency braking systems, which use sensors such as ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback